IRVINE, Calif.--(BUSINESS WIRE)--The Board of Directors of Allergan, Inc. (NYSE: AGN) (“Allergan” or the “Company”) today issued the following statement:
There has recently been significant and potentially distracting market speculation regarding Allergan, so, as the Company’s Board of Directors, we think it is important to reiterate our unanimous perspective. Our conclusion that Valeant’s offer is grossly inadequate and substantially undervalues Allergan remains unchanged. We continue to believe strongly that Valeant’s offer does not appropriately reflect the underlying value of Allergan’s assets, operations and prospects, including Allergan’s industry-leading franchises of global scale and its projected growth opportunities.
To that point, we note that since Valeant Pharmaceuticals International, Inc. (“Valeant”) first made its unsolicited proposal to acquire Allergan on April 22, 2014, Allergan’s already leading growth trajectory has been accelerated through:
Help employers find you! Check out all the jobs and post your resume.
